Skip to content
Open access · CC-BY via OpenAlex

In vivo distribution of α-synuclein in multiple tissues and biofluids in Parkinson disease

Lana M. Chahine, Thomas G. Beach, Michael C. Brumm, Charles H. Adler, Christopher S. Coffey, Sherri Mosovsky, Chelsea Caspell‐Garcia, Geidy E. Serrano, David G. Muñoz, Charles L. White, John F. Crary, Danna L. Jennings, Peggy Taylor, Tatiana Foroud, Vanessa Arnedo

Neurology · 2020 · ▲ 150 citations

Abstract

OBJECTIVE: The Systemic Synuclein Sampling Study (S4) measured α-synuclein in multiple tissues and biofluids within the same patients with Parkinson disease (PD) vs healthy controls (HCs). METHODS: S4 was a 6-site cross-sectional observational study of participants with early, moderate, or advanced PD and HCs. Motor and nonmotor measures and dopamine transporter SPECT were obtained. Biopsies of skin, colon, submandibular gland (SMG), CSF, saliva, and blood were collected. Tissue biopsy sections were stained with 5C12 monoclonal antibody against pathologic α-synuclein; digital images were interpreted by neuropathologists blinded to diagnosis. Biofluid total α-synuclein was quantified using ELISA. RESULTS: The final cohort included 59 patients with PD and 21 HCs. CSF α-synuclein was lower in patients with PD vs HCs; sensitivity/specificity of CSF α-synuclein for PD diagnosis was 87.0%/63.2%, respectively. Sensitivity of α-synuclein immunoreactivity for PD diagnosis was 56.1% for SMG and 24.1% for skin; specificity was 92.9% and 100%, respectively. There were no significant relationships between different measures of α-synuclein within participants. CONCLUSIONS: S4 confirms lower total α-synuclein levels in CSF in patients with PD compared to HCs, but specificity is low. In contrast, α-synuclein immunoreactivity in skin and SMG is specific for PD but sensitivity is low. Relationships within participants across different tissues and biofluids could not be demonstrated. Measures of pathologic forms of α-synuclein with higher accuracy are critically needed. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that total CSF α-synuclein does not accurately distinguish patients with PD from HCs, and that monoclonal antibody staining for SMG and skin total α-synuclein is specific but not sensitive for PD diagnosis.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1212/wnl.0000000000010404
Canonical
link ↗
Fetched
2026-10-29 MST

Cite this

APA
Chahine, L.M., Beach, T.G., Brumm, M.C., Adler, C.H., Coffey, C.S., Mosovsky, S., Caspell‐Garcia, C., Serrano, G.E., Muñoz, D.G., White, C.L., Crary, J.F., Jennings, D.L., Taylor, P., Foroud, T., Arnedo, V., Kopil, C., Riley, L., Dave, K.D., Mollenhauer, B., &amp; Study, F.T.S.S.S. (2020). In vivo distribution of α-synuclein in multiple tissues and biofluids in Parkinson disease. <em>Neurology</em>. https://doi.org/10.1212/wnl.0000000000010404
Vancouver
Chahine LM, Beach TG, Brumm MC, Adler CH, Coffey CS, Mosovsky S, et al. In vivo distribution of α-synuclein in multiple tissues and biofluids in Parkinson disease. Neurology. 2020. doi:10.1212/wnl.0000000000010404.
BibTeX
@article{lana2020Invivo, title = {In vivo distribution of α-synuclein in multiple tissues and biofluids in Parkinson disease}, author = {Lana M. Chahine and Thomas G. Beach and Michael C. Brumm and Charles H. Adler and Christopher S. Coffey and Sherri Mosovsky and Chelsea Caspell‐Garcia and Geidy E. Serrano and David G. Muñoz and Charles L. White and John F. Crary and Danna L. Jennings and Peggy Taylor and Tatiana Foroud and Vanessa Arnedo and Catherine Kopil and Lindsey Riley and Kuldip D. Dave and Brit Mollenhauer and for the Systemic Synuclein Sampling Study}, journal = {Neurology}, year = {2020}, doi = {10.1212/wnl.0000000000010404}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings